After a successful appeal, reimbursement authority NICE has said the companies' files will now be sent back to the appraisal ...

After a strong start to the year, the value of biotech financings has tailed off a little, but March has seen a clutch of $50 ...

February was a light month for agency and consultancy news, but a few interesting changes came through. Read on for the ...

Axtria Ignite 2026 returns June 10–11 in Princeton, New Jersey, and this year’s theme is “Industrializing Intelligence: The Agentic Enterprise.” What does that mean? Consider this: Somewhere right now ...

First developed in the 1960s, they are supported by extensive clinical evidence and recommended by leading professional ...

Novo Nordisk is facing generics of its GLP-1 drug in India, Atrogi is testing a new weight loss approach, and there's new ...

Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity, a rare condition in which damage to or a malfunction of the hypothalamus leads to excessive weight gain ...

Novartis has reached an agreement to buy a PI3K-targeting drug for breast cancer from Synnovation Therapeutics, paying a hefty $2 billion upfront for the asset, which is in phase 1/2 testing. The deal ...

Ask a pharma commercial team where lung cancer patients are treated in France and most will point to major academic centres ...

This breakthrough has accelerated peptide drug development across multiple therapeutic areas, including cardiovascular ...

The aligned pathway for UK drugs regulator MHRA and reimbursement authority NICE – aimed at slashing the time it takes for ...

New draft guidance from the FDA is urging pharma companies to accelerate efforts to transition from animal testing to ...